ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 22 December 2015 that on 17 December 2015, Nigel Clifford, a Non-Executive Director of the Company, purchased 33,370 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 44.95 pence per share, and his spouse, Jeanette Clifford, also purchased 33,370 Ordinary Shares on the same date at the same price.
Following this transaction, Mr Clifford's total beneficial interest in the Company is 180,663 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar
Notes to editors:
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 87 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.